Business Context and Reporting Period
This Form 6-K filing by Morria Biopharmaceuticals PLC (commonly known as Celsus Therapeutics) is dated April 30, 2013. The filing reports a corporate governance update rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and contains no financial data.
Material Changes
On April 30, 2013, the Company announced that Fredric Price has joined its board of directors. Mr. Price brings extensive experience in the biopharmaceutical sector, including prior roles as Executive Chairman of Chiasma and Omrix Biopharmaceuticals, and former CEO of BioMarin Pharmaceutical.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operational outlook, or specific risk factors. The primary purpose is to disclose the addition of a new director with a background in strategic collaborations and executive leadership.
Key Facts for Investor Verification
- Confirm the official appointment of Fredric Price to the Board of Directors.
- Review the attached press release (Exhibit 99.1) for details on Mr. Price's specific responsibilities.
- Note that this filing does not include financial performance data for the period.